These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18459949)

  • 1. Lipoprotein(a) in patients initiating antiretroviral therapy.
    Mauss S; Berger F; Schmutz G; Henke J; Richter WO
    HIV Med; 2008 Jul; 9(6):415-20. PubMed ID: 18459949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class of antiretroviral drugs and the risk of myocardial infarction.
    ; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
    N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy.
    Melvin AJ; Kang M; Hitti J; Livingston E; Cohn SE; Stocker V; Ross AC; Watts H; McComsey GA
    Antivir Ther; 2008; 13(3):349-55. PubMed ID: 18572747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
    Martínez E; Domingo P; Galindo MJ; Milinkovic A; Arroyo JA; Baldovi F; Larrousse M; León A; de Lazzari E; Gatell JM
    Clin Infect Dis; 2004 Apr; 38(7):1017-23. PubMed ID: 15034836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
    Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
    HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
    AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic renal failure among HIV-1-infected patients.
    Mocroft A; Kirk O; Gatell J; Reiss P; Gargalianos P; Zilmer K; Beniowski M; Viard JP; Staszewski S; Lundgren JD
    AIDS; 2007 May; 21(9):1119-27. PubMed ID: 17502722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients.
    Roberts AD; Muesing RA; Parenti DM; Hsia J; Wasserman AG; Simon GL
    Clin Infect Dis; 1999 Aug; 29(2):441-3. PubMed ID: 10476757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
    Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
    Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents.
    Arrington-Sanders R; Hutton N; Siberry GK
    Pediatr Infect Dis J; 2006 Nov; 25(11):1044-8. PubMed ID: 17072128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.